go-v.orgcodex
Menu
Page tools

codex · Chemistry

Vorolanib

Diagram for Vorolanib
Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but fail · image: Wikimedia Commons

Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed. Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration. and its azidated and chlorinated version, termed EYE1118, is designed to be targeted to the eye by natural light to reduce retinal and choroidal neovascularization locally.

It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).

Wikipedia contributors, "Vorolanib", Wikipedia, revision 1385733193, retrieved 20 November 2026, source, CC BY-SA 4.0.

More Chemistry · Search the codex